Company intelligence / Profile preview

CGBS

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

Cell and Gene BioSolutions (CGBS) is a specialized contract development and manufacturing organization (CDMO) focused on the cell and gene therapy (CGT) sector. The company provides end-to-end services ranging from early-stage process development and analytical testing to large-scale GMP manufacturing of viral vectors, plasmid DNA, and mRNA. CGBS aims to accelerate the clinical translation of advanced therapies by offering high-quality manufacturing solutions and regulatory support for global biopharmaceutical clients. Their expertise spans various modalities, including CAR-T cells, stem cells, and exosome-based products.

Modalities: Cell therapyGene therapymRNA-based drugsPlasmid DNAViral vectorExosome-based therapy
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on CGBS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CGBS.

Explore the full profile